The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
Copper Exposure, Sensitivity, and Long-Term Safety Gaps Copper is biologically essential, but copper exposure is not automatically harmless, especially if a formulation changes systemic exposure or bypasses normal skin barriers
Capehorn M, Catarig A-M, Furberg J, Janez A, Price H, Tadayon S, Vergs B, Marre M
Pickart was studying liver tissue regeneration and noticed that a small peptide fraction isolated from human plasma significantly accelerated repair in older liver cells, restoring their behavior to something closer to younger cells